Corline Biomedical AB (STO:CLBIO)

Market Cap	423.90M +85.2%
Revenue (ttm)	8.88M -62.3%
Net Income	-23.85M
EPS	-0.99
Shares Out	25.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,343
Average Volume	16,167
Open	17.35
Previous Close	16.55
Day's Range	15.75 - 17.35
52-Week Range	7.90 - 27.20
Beta	0.39
RSI	40.85
Earnings Date	Feb 17, 2026

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CLBIO

Financial Performance

In 2024, Corline Biomedical AB's revenue was 17.27 million, a decrease of -51.37% compared to the previous year's 35.52 million. Losses were -23.19 million, 1182.1% more than in 2023.